NCI-2024-07565

A First-In-Human, Phase 1, Dose-Escalation Study of SGR-3515 In Participants with Advanced Solid Tumors

This research study is testing a new medicine, called SGR‑3515, to see if it's safe and can be used in people with advanced solid tumors (like lung, breast, ovarian cancers) whose cancer has continued to grow despite other treatments. SGR‑3515 is a targeted drug that blocks two important proteins, Wee1 and Myt1, which help cancer cells fix damage and grow. By blocking these, the drug may make it harder for cancer cells to survive or divide properly. The study will determine if it's safe, how much to give, and whether it might help fight the cancer.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06463340

Clinical Trial Site: Sinai

To see all available clinical trials click here.